Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 1/2013

01-02-2013 | Hypertension and the Kidney (RM Carey and A Mimran, Section Editors)

Direct Activation of ENaC by Angiotensin II: Recent Advances and New Insights

Authors: Oleg Zaika, Mykola Mamenko, Alexander Staruschenko, Oleh Pochynyuk

Published in: Current Hypertension Reports | Issue 1/2013

Login to get access

Abstract

Angiotensin II (Ang II) is the principal effector of the renin–angiotensin–aldosterone system (RAAS). It initiates myriad processes in multiple organs integrated to increase circulating volume and elevate systemic blood pressure. In the kidney, Ang II stimulates renal tubular water and salt reabsorption causing antinatriuresis and antidiuresis. Activation of the RAAS is known to enhance activity of the epithelial Na+ channel (ENaC) in the aldosterone-sensitive distal nephron. In addition to its well described stimulatory actions on aldosterone secretion, Ang II is also capable of directly increasing ENaC activity. In this brief review, we discuss recent findings about non-classical Ang II actions on ENaC and speculate about its relevance for renal sodium handling.
Literature
1.
Guyton AC. Blood pressure control-special role of the kidneys and body fluids. Science. 1991;252:1813–6.PubMedCrossRef
2.
Crowley SD, Coffman TM. Recent advances involving the renin–angiotensin system. Exp Cell Res. 2012;318:1049–56.PubMedCrossRef
3.
Konner M, Eaton SB. Paleolithic nutrition: twenty-five years later. Nutr Clin Pract. 2010;25:594–602.PubMedCrossRef
4.
Eaton SB, Konner M. Paleolithic nutrition. A consideration of its nature and current implications. N Engl J Med. 1985;312:283–9.PubMedCrossRef
5.
Khawaja Z, Wilcox CS. Role of the kidneys in resistant hypertension. Int J Hypertens. 2011;2011:143471.
6.
Meneton P, Jeunemaitre X, de Wardener HE, MacGregor GA. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev. 2005;85:679–715.PubMedCrossRef
7.
• Staruschenko A. Regulation of Transport in the Connecting Tubule and Cortical Collecting Duct. Compr Physiol. 2012;2:1541–84. This comprehensive review manuscript provides up-to-date overview of mechanisms controlling channels and transporters in the distal part of renal nephron.
8.
Sun Y, Zhang JN, Zhao D, et al. Role of the epithelial sodium channel in salt-sensitive hypertension. Acta Pharmacol Sin. 2011;32:789–97.PubMedCrossRef
9.
Soundararajan R, Pearce D, Hughey RP, Kleyman TR. Role of epithelial sodium channels and their regulators in hypertension. J Biol Chem. 2010;285:30363–9.PubMedCrossRef
10.
Eaton DC, Malik B, Saxena NC, et al. Mechanisms of aldosterone's action on epithelial Na+ transport. J Membr Biol. 2001;184:313–9.PubMedCrossRef
11.
Garty H, Palmer LG. Epithelial sodium channels: function, structure, and regulation. Physiol Rev. 1997;77:359–96.PubMed
12.
Hummler E. Implication of ENaC in salt-sensitive hypertension. J Steroid Biochem Mol Biol. 1999;69:385–90.PubMedCrossRef
13.
Hummler E. Epithelial sodium channel, salt intake, and hypertension. Curr Hypertens Rep. 2003;5:11–8.PubMedCrossRef
14.
Schild L. The epithelial sodium channel: from molecule to disease. Rev Physiol Biochem Pharmacol. 2004;151:93–107.PubMedCrossRef
15.
Schild L, Kellenberger S. Structure function relationships of ENaC and its role in sodium handling. Adv Exp Med Biol. 2001;502:305–14.PubMed
16.
Stockand JD. New ideas about aldosterone signaling in epithelia. Am J Physiol Renal Physiol. 2002;282:F559–76.PubMed
17.
Hansson JH, Nelson-Williams C, Suzuki H, et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet. 1995;11:76–82.PubMedCrossRef
18.
Hansson JH, Schild L, Lu Y, et al. A de novo missense mutation of the beta subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc Natl Acad Sci U S A. 1995;92:11495–9.PubMedCrossRef
19.
Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545–56.PubMedCrossRef
20.
Schild L. The ENaC channel as the primary determinant of two human diseases: Liddle syndrome and pseudohypoaldosteronism. Nephrologie. 1996;17:395–400.PubMed
21.
Shimkets RA, Warnock DG, Bositis CM, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell. 1994;79:407–14.PubMedCrossRef
22.
Schafer JA. Abnormal regulation of ENaC: syndromes of salt retention and salt wasting by the collecting duct. Am J Physiol Renal Physiol. 2002;283:F221–35.PubMed
23.
Palmer LG, Frindt G. Regulation of apical membrane Na and K channels in rat renal collecting tubules by aldosterone. Semin Nephrol. 1992;12:37–43.PubMed
24.
Frindt G, Palmer LG. Surface expression of sodium channels and transporters in rat kidney: effects of dietary sodium. Am J Physiol Renal Physiol. 2009;297:F1249–55.PubMedCrossRef
25.
Verrey F. Transcriptional control of sodium transport in tight epithelial by adrenal steroids. J Membr Biol. 1995;144:93–110.PubMed
26.
Warnock DG. Aldosterone-related genetic effects in hypertension. Curr Hypertens Rep. 2000;2:295–301.PubMedCrossRef
27.
Makhanova N, Lee G, Takahashi N, et al. Kidney function in mice lacking aldosterone. Am J Physiol Renal Physiol. 2006;290:F61–9.PubMedCrossRef
28.
Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov. 2002;1:621–36.PubMedCrossRef
29.
Arroyo JP, Ronzaud C, Lagnaz D, et al. Aldosterone paradox: differential regulation of ion transport in distal nephron. Physiology (Bethesda). 2011;26:115–23.CrossRef
30.
Berger S, Bleich M, Schmid W, et al. Mineralocorticoid receptor knockout mice: pathophysiology of Na+ metabolism. Proc Natl Acad Sci U S A. 1998;95:9424–9.PubMedCrossRef
31.
• Mironova E, Bugaj V, Roos KP, et al. Aldosterone-independent regulation of the epithelial Na+ channel (ENaC) by vasopressin in adrenalectomized mice. Proc Natl Acad Sci U S A. 2012;109:10095–100. This manuscript convincingly demonstrates that aldosterone is sufficient but not necessary for ENaC activity in the distal nephron. Ablation of adrenal gland results in compensatory regulation of ENaC by vasopressin. This shifts the role of ENaC from protecting Na + balance to promoting water reabsorption.
32.
Pratt JH. Central role for ENaC in development of hypertension. J Am Soc Nephrol. 2001;16:3154–9.CrossRef
33.
Ito M, Oliverio MI, Mannon PJ, et al. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci U S A. 1995;92:3521–5.PubMedCrossRef
34.
Oliverio MI, Best CF, Smithies O, Coffman TM. Regulation of sodium balance and blood pressure by the AT1A receptor for angiotensin II. Hypertension. 2000;35:550–4.PubMedCrossRef
35.
Crowley SD, Gurley SB, Herrera MJ, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006;103:17985–90.PubMedCrossRef
36.
Crowley SD, Zhang J, Herrera M, et al. Role of AT1 receptor-mediated salt retention in angiotensin II-dependent hypertension. Am J Physiol Renal Physiol. 2011;301:F1124–30.PubMedCrossRef
37.
Harrison-Bernard LM, Navar LG, Ho MM, et al. Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol. 1997;273:F170–7.PubMed
38.
Ozono R, Wang ZQ, Moore AF, et al. Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension. 1997;30:1238–46.PubMedCrossRef
39.
Miyata N, Park F, Li XF, Cowley Jr AW. Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney. Am J Physiol. 1999;277:F437–46.PubMed
40.
Gurley SB, Riquier-Brison AD, Schnermann J, et al. AT1a angiotensin receptors in the renal proximal tubule regulate blood pressure. Cell Metab. 2011;13:469–75.PubMedCrossRef
41.
Brooks HL, Allred AJ, Beutler KT, et al. Targeted proteomic profiling of renal Na+ transporter and channel abundances in angiotensin II type 1a receptor knockout mice. Hypertension. 2002;39:470–3.PubMedCrossRef
42.
•• Stegbauer J, Gurley SB, Sparks MA, et al. AT1 receptors in the collecting duct directly modulate the concentration of urine. J Am Soc Nephrol. 2011;22:2237–46. This study provides first evidence that collecting duct AT 1a receptors are necessary for normal kidney function. While it does not affect ENaC abundance under normal sodium intake, disruption of AT 1a in the principal cells impairs urinary concentrating ability.
43.
Saavedra JM, Benicky J, Zhou J. Angiotensin II: multitasking in the brain. J Hypertens Suppl. 2006;24:S131–7.PubMedCrossRef
44.
Leung PS. The physiology of a local renin-angiotensin system in the pancreas. J Physiol. 2007;580:31–7.PubMedCrossRef
45.
Bugaj V, Pochynyuk O, Stockand JD. Activation of the epithelial Na+ channel in the collecting duct by vasopressin contributes to water reabsorption. Am J Physiol Renal Physiol. 2009;297:F1411–8.PubMedCrossRef
46.
Staruschenko A, Pochynyuk O, Vandewalle A, et al. Acute Regulation of the Epithelial Na+ Channel by Phosphatidylinositide 3-OH Kinase Signaling in Native Collecting Duct Principal Cells. J Am Soc Nephrol. 2007;18:1652–61.PubMedCrossRef
47.
•• Mamenko M, Zaika O, Ilatovskaya DV, et al. Angiotensin II Increases Activity of the Epithelial Na+ Channel (ENaC) in Distal Nephron Additively to Aldosterone. J Biol Chem. 2012;287:660–71. Using physiologically relevant tissue: split-opened distal nephrons of mice, this study demonstrates that Ang II directly controls ENaC activity. This regulation is complex and includes an acute activation of functional ENaC via generation of ROS as well as more chronic effect on ENaC trafficking to the apical plasma membrane. Furthermore, the effect of Ang II on ENaC is independent of aldosterone status.
48.
Peti-Peterdi J, Warnock DG, Bell PD. Angiotensin II directly stimulates ENaC activity in the cortical collecting duct via AT1 receptors. J Am Soc Nephrol. 2002;13:1131–5.PubMedCrossRef
49.
•• Sun P, Yue P, Wang WH. Angiotensin II stimulates epithelial sodium channels in the cortical collecting duct of the rat kidney. Am J Physiol Renal Physiol. 2012;302: F679–F687. Synchronous with Ref 47, this study demonstrates that Ang II stimulates ENaC in rat CCDs through a Ca 2+ -independent PKC pathway, activation of NOX and superoxide generation.
50.
Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 2006;20:953–70.
51.
Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003;12:70–88.PubMedCrossRef
52.
Babilonia E, Lin D, Zhang Y, et al. Role of gp91phox -containing NADPH oxidase in mediating the effect of K restriction on ROMK channels and renal K excretion. J Am Soc Nephrol. 2007;18:2037–45.PubMedCrossRef
53.
Sun P, Lin DH, Yue P, et al. High potassium intake enhances the inhibitory effect of 11,12-EET on ENaC. J Am Soc Nephrol. 2010;21:1667–77.PubMedCrossRef
54.
Wei Y, Lin DH, Kemp R, et al. Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways. J Gen Physiol. 2004;124:719–27.PubMedCrossRef
55.
Pavlov TS, Ilatovskaya DV, Levchenko V, et al. Effects of cytochrome P-450 metabolites of arachidonic acid on the epithelial sodium channel (ENaC). Am J Physiol Renal Physiol. 2011;301:F672–81.PubMedCrossRef
56.
• Ma HP. (Hydrogen peroxide stimulates the epithelial sodium channel through a phosphatidylinositide 3-kinase dependent pathway. J Biol Chem. 2011;286(37):32444–53. This study provides the first evidence that ROS and particularly H 2 O 2 directly activate ENaC. As discussed in this manuscript, ROS could serve as downstream signaling molecules for direct effect of Ang II.
57.
Bharatula M, Hussain T, Lokhandwala MF. Angiotensin II AT1 receptor/signaling mechanisms in the biphasic effect of the peptide on proximal tubular Na+, K+-ATPase. Clin Exp Hypertens. 1998;20:465–80.PubMedCrossRef
58.
Pacha J, Frindt G, Antonian L, et al. Regulation of Na channels of the rat cortical collecting tubule by aldosterone. J Gen Physiol. 1993;102:25–42.
59.
Loffing J, Zecevic M, Feraille E, et al. Aldosterone induces rapid apical translocation of ENaC in early portion of renal collecting system: possible role of SGK. Am J Physiol Renal Physiol. 2001;280:F675–82.PubMed
60.
61.
Rotin D, Staub O. Role of the ubiquitin system in regulating ion transport. Pflugers Arch. 2011;461:1–21.PubMedCrossRef
62.
Loffing J, Korbmacher C. Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC). Pflugers Arch. 2009;458:111–35.PubMedCrossRef
63.
Kahle KT, Rinehart J, Giebisch G, et al. A novel protein kinase signaling pathway essential for blood pressure regulation in humans. Trends Endocrinol Metab. 2008;19:91–5.PubMedCrossRef
64.
Wilson FH, Disse-Nicodeme S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science. 2001;293:1107–12.
65.
Arroyo JP, Gamba G. Advances in WNK signaling of salt and potassium metabolism: clinical implications. Am J Nephrol. 2012;35:379–86.PubMedCrossRef
66.
67.
Hoorn EJ, Nelson JH, McCormick JA, Ellison DH. The WNK kinase network regulating sodium, potassium, and blood pressure. J Am Soc Nephrol. 2011;22:605–14.PubMedCrossRef
68.
Kahle KT, Ring AM, Lifton RP. Molecular physiology of the WNK kinases. Annu Rev Physiol. 2008;70:329–55.PubMedCrossRef
69.
Loffing J, Loffing-Cueni D, Valderrabano V, et al. Distribution of transcellular calcium and sodium transport pathways along mouse distal nephron. Am J Physiol Renal Physiol. 2001;281:F1021–7.PubMed
70.
Loffing J, Kaissling B. Sodium and calcium transport pathways along the mammalian distal nephron: from rabbit to human. Am J Physiol Renal Physiol. 2003;284:F628–43.PubMed
71.
Obermuller N, Bernstein P, Velazquez H, et al. Expression of the thiazide-sensitive Na-Cl cotransporter in rat and human kidney. Am J Physiol. 1995;269:F900–10.PubMed
72.
LeHoux JG, Bird IM, Rainey WE, et al. Both low sodium and high potassium intake increase the level of adrenal angiotensin-II receptor type 1, but not that of adrenocorticotropin receptor. Endocrinology. 1994;134:776–82.PubMedCrossRef
73.
Kim GH, Masilamani S, Turner R, et al. The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein. Proc Natl Acad Sci U S A. 1998;95:14552–7.PubMedCrossRef
74.
Nielsen J, Kwon TH, Masilamani S, et al. Sodium transporter abundance profiling in kidney: effect of spironolactone. Am J Physiol Renal Physiol. 2002;283:F923–33.PubMed
75.
Vallon V, Schroth J, Lang F, et al. Expression and phosphorylation of the Na+-Cl- cotransporter NCC in vivo is regulated by dietary salt, potassium, and SGK1. Am J Physiol Renal Physiol. 2009;297:F704–12.PubMedCrossRef
76.
Frindt G, Palmer LG. Effects of dietary K on cell-surface expression of renal ion channels and transporters. Am J Physiol Renal Physiol. 2010;299(4):F890–7.PubMedCrossRef
77.
Pluznick JL, Sansom SC. BK channels in the kidney: role in K+ secretion and localization of molecular components. Am J Physiol Renal Physiol. 2006;291:F517–29.PubMedCrossRef
78.
San-Cristobal P, Pacheco-Alvarez D, Richardson C, et al. Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway. Proc Natl Acad Sci U S A. 2009;106:4384–9.PubMedCrossRef
79.
Sandberg MB, Riquier AD, Pihakaski-Maunsbach K, et al. ANG II provokes acute trafficking of distal tubule Na+-Cl- cotransporter to apical membrane. Am J Physiol Renal Physiol. 2007;293:F662–9.PubMedCrossRef
80.
van der Lubbe N, Lim CH, Meima ME, et al. Aldosterone does not require angiotensin II to activate NCC through a WNK4-SPAK-dependent pathway. Pflugers Arch 2012;463:853–63.
81.
van der Lubbe N, Lim CH, Fenton RA, et al. Angiotensin II induces phosphorylation of the thiazide-sensitive sodium chloride cotransporter independent of aldosterone. Kidney Int. 2011;79:66–76.
82.
Frindt G, Palmer LG. K+ secretion in the rat kidney: Na+ channel-dependent and -independent mechanisms. Am J Physiol Renal Physiol. 2009;297:F389–96.PubMedCrossRef
83.
• Yue P, Sun P, Lin DH, et al. Angiotensin II diminishes the effect of SGK1 on the WNK4-mediated inhibition of ROMK1 channels. Kidney Int. 2011;79:423–31. By demonstrating that Ang II inhibits ROMK channels in the cortical collecting duct of rats on a low sodium diet, this study suggests that Ang II has an important role in suppressing potassium secretion during volume depletion.
84.
Wei Y, Zavilowitz B, Satlin LM, Wang WH. Angiotensin II inhibits the ROMK-like small conductance K channel in renal cortical collecting duct during dietary potassium restriction. J Biol Chem. 2007;282:6455–62.PubMedCrossRef
85.
Gonzalez-Villalobos RA, Seth DM, Satou R, et al. Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice. Am J Physiol Renal Physiol. 2008;295:F772–9.PubMedCrossRef
86.
Gonzalez-Villalobos RA, Satou R, Ohashi N, et al. Intrarenal mouse renin-angiotensin system during ANG II-induced hypertension and ACE inhibition. Am J Physiol Renal Physiol. 2010;298:F150–7.PubMedCrossRef
87.
Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H. Regulation of intrarenal angiotensin II in hypertension. Hypertension. 2002;39:316–22.PubMedCrossRef
88.
Rohrwasser A, Morgan T, Dillon HF, et al. Elements of a paracrine tubular renin-angiotensin system along the entire nephron. Hypertension. 1999;34:1265–74.PubMedCrossRef
89.
Navar LG, Prieto MC, Satou R, Kobori H. Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. Curr Opin Pharmacol. 2011;11:180–6.PubMedCrossRef
90.
Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol. 2010;31:541–50.PubMedCrossRef
91.
Casarini DE, Boim MA, Stella RC, et al. Angiotensin I-converting enzyme activity in tubular fluid along the rat nephron. Am J Physiol. 1997;272:F405–9.PubMed
92.
Komlosi P, Fuson AL, Fintha A, et al. Angiotensin I conversion to angiotensin II stimulates cortical collecting duct sodium transport. Hypertension. 2003;42:195–9.PubMedCrossRef
93.
Prieto-Carrasquero MC, Harrison-Bernard LM, Kobori H, et al. Enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Hypertension. 2004;44:223–9.PubMedCrossRef
94.
Prieto-Carrasquero MC, Botros FT, Pagan J, et al. Collecting duct renin is upregulated in both kidneys of 2-kidney, 1-clip goldblatt hypertensive rats. Hypertension. 2008;51:1590–6.PubMedCrossRef
95.
Chandramohan G, Bai Y, Norris K, et al. Effects of dietary salt on intrarenal angiotensin system, NAD(P)H oxidase, COX-2, MCP-1 and PAI-1 expressions and NF-kappaB activity in salt-sensitive and -resistant rat kidneys. Am J Nephrol. 2008;28:158–67.PubMedCrossRef
96.
De MC, Das S, Lund H, Mattson DL. T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol. 2010;298:R1136–42.CrossRef
97.
Kakizoe Y, Kitamura K, Ko T, Wakida N, Maekawa A, Miyoshi T, et al. Aberrant ENaC activation in Dahl salt-sensitive rats. J Hypertens. 2009;27:1679–89.PubMedCrossRef
98.
Peti-Peterdi J. High glucose and renin release: the role of succinate and GPR91. Kidney Int. 2010;78:1214–7.PubMedCrossRef
99.
Toma I, Kang JJ, Sipos A, Vargas S, Bansal E, Hanner F, et al. Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney. J Clin Invest. 2008;118:2526–34.PubMed
Metadata
Title
Direct Activation of ENaC by Angiotensin II: Recent Advances and New Insights
Authors
Oleg Zaika
Mykola Mamenko
Alexander Staruschenko
Oleh Pochynyuk
Publication date
01-02-2013
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 1/2013
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-012-0316-1

Other articles of this Issue 1/2013

Current Hypertension Reports 1/2013 Go to the issue

Hypertension and the Kidney (RM Carey and A Mimran, Section Editors)

Opportunities for Targeting the Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas Receptor Pathway in Hypertension

Hypertension and the Kidney (RM Carey and A Mimran, Section Editors)

Update on the Angiotensin AT2 Receptor

Hypertension and the Kidney (RM Carey and A Mimran, Section Editors)

Pathophysiology of Hypertension in the Absence of Nitric Oxide/Cyclic GMP Signaling

Hypertension and the Kidney (RM Carey and A Mimran, Section Editors)

The Role of Type 1 Angiotensin Receptors on T Lymphocytes in Cardiovascular and Renal Diseases

Hypertension and the Kidney (RM Carey and A Mimran, Section Editors)

Angiotensinergic Innervation of the Kidney: Present Knowledge and Its Significance

Hypertension and the Kidney (RM Carey and A Mimran, Section Editors)

Treatment of Arterial Remodeling in Essential Hypertension
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits